MindWalk Holdings filed patent EP26187897.9 on July 15, adding a computational layer atop its foundational HYFT patent, EP3881326A1.1 The filing organizes the biological meaning behind identified patterns into a form reusable across MindWalk's infrastructure and customer AI workflows.1
HYFT Technology encodes roughly 660 million biological patterns — universal fingerprints linking sequence, structure and function.2 MindWalk's bet: representing biology itself, not raw compute, is the hard problem and the durable advantage.2
NVIDIA is chasing the same layer from a different angle. Its BioNeMo platform now anchors lab-in-the-loop partnerships with Thermo Fisher and Eli Lilly, positioning NVIDIA as connective tissue linking wet-lab experiments to AI models. Basecamp Research's EDEN, Boltz Lab, Owkin's OwkinZero and Edison Scientific's Kosmos are building competing foundation-model platforms for biology, each betting that owning the representation layer matters more than owning lab automation.
Incumbent pharma is reallocating capital toward this stack rather than building it in-house. Novo Nordisk closed its internal cell therapy unit and licensed a Parkinson's disease asset to the AI-driven Cellular Intelligence platform.3 The move came alongside strong core earnings and a 24.9% 30-day stock gain.3 Investors read the shift as additive outsourcing, not weakness.
The through-line: foundation-model platforms that represent biology computationally are absorbing work once run inside pharma R&D departments — from target identification to licensing decisions on clinical assets. NVIDIA's partnerships and MindWalk's patent expansion suggest the infrastructure layer for drug discovery is consolidating around a handful of AI-native platforms, with legacy pharma increasingly renting rather than owning that capability.